Lu-Wei Fu

Design and synthesis of novel peptide-based degraders against wild type and gatekeeper mutants FGFR1 for the treatment of NSCLC.

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related morbidity worldwide, with fibroblast growth factor receptor 1 (FGFR1) playing a pivotal role in its pathogenesis and progression. Although FGFR1-targeted therapies, particularly tyrosine kinase inhibitors (TKIs), have shown clinical efficacy, their...